IMR Press / FBS / Volume 9 / Issue 1 / DOI: 10.2741/S470

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


TGF-beta1, WNT, and SHH signaling in tumor progression and in fibrotic diseases

Show Less
1 IEOS-CNR, Via Pansini 5, 80014 Naples, Italy
2 Dipartimento di Medicina Molecolare e Biotecnologie Mediche, University of Naples Federico II, Via Pansini 5, 80014 Naples, Italy
3 IRCCS SDN, Via Gianturco 113, 80431, Naples, Italy

*Author to whom correspondence should be addressed.

Front. Biosci. (Schol Ed) 2017, 9(1), 31–45;
Published: 1 January 2017

Activation of resting fibroblasts to myofibroblasts characterizes several physiological and pathological conditions, from wound healing to aggressive metastatic cancers. In tissue damage, including wound healing, fibroblasts are activated in response to injury for a limited period of time to stimulate the healing process. Similar biological mechanisms are maintained in pathological conditions, e.g., scleroderma and cancer, where myofibroblasts persist in producing cytokines and growth factors to drive the development of fibrosis and the progression of disease. Studies characterizing the bi-directional signal transduction pathways between cancer cells and stromal cells have suggested novel druggable targets that may function in both the inhibition of fibrotic reactions in cancer stroma and in the inhibition of fibrotic diseases. In this review, we focus on transforming growth factor β (TGFβ), int/Wingless (WNT), and sonic hedgehog (SHH) signal transduction pathways and describe small molecule inhibitors that are used in phase I/II clinical trials to treat fibrosis or fibrotic cancers.

Systemic Sclerosis
Clinical Trial
Back to top